{
  "metadata": {
    "case_id": 49,
    "model": "Claude-4.5-Sonnet",
    "timestamp": "2025-11-29T16:32:43.873568",
    "total_alignments": 4,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/49_NCT03388164.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/Claude-4.5-Sonnet/49_Claude-4.5-Sonnet.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.72,
          0.55
        ],
        [
          0.96,
          0.78
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.55,
          "status": "matched",
          "ref_item": {
            "label": "Escitalopram + RT2CK17",
            "type": "ACTIVE_COMPARATOR",
            "description": "10mg escitalopram + 5mg RT2CK17 will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the placebo comparator by a local compounding pharmacy in Tulsa, Oklahoma.",
            "interventionNames": [
              "Drug: Escitalopram + RT2CK17"
            ]
          },
          "pred_item": {
            "label": "Methylphenidate + Escitalopram",
            "type": "EXPERIMENTAL",
            "description": "5 mg methylphenidate (MPH) + 10 mg escitalopram encapsulated into one capsule, with option to escalate escitalopram dose to 20 mg at week 4 based on lack of clinical improvement.",
            "interventionNames": [
              "Drug: Methylphenidate + Escitalopram",
              "Device: Medication Electronic Monitoring System (MEMS)"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "label": "Escitalopram + Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "10mg escitalopram + 5mg placebo will be given orally and encapsulated into one capsule, once per day for 8 weeks. The capsules will be produced in the same manner as the active comparator by a local compounding pharmacy in Tulsa, Oklahoma.",
            "interventionNames": [
              "Drug: Escitalopram + Placebo"
            ]
          },
          "pred_item": {
            "label": "Placebo + Escitalopram",
            "type": "PLACEBO_COMPARATOR",
            "description": "5 mg placebo + 10 mg escitalopram encapsulated into one capsule, with option to escalate escitalopram dose to 20 mg at week 4 based on lack of clinical improvement.",
            "interventionNames": [
              "Drug: Placebo + Escitalopram",
              "Device: Medication Electronic Monitoring System (MEMS)"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.7,
          0.55,
          0.2
        ],
        [
          0.98,
          0.6,
          0.2
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 1,
          "score": 0.55,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Escitalopram + RT2CK17",
            "description": "Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.",
            "armGroupLabels": [
              "Escitalopram + RT2CK17"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Methylphenidate + Escitalopram",
            "description": "Participants received 5 mg methylphenidate + 10 mg escitalopram daily for 8 weeks. Dose could be increased to 5 mg methylphenidate + 20 mg escitalopram at week 4 if clinically indicated.",
            "armGroupLabels": [
              "Methylphenidate + Escitalopram"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 0,
          "score": 0.98,
          "status": "matched",
          "ref_item": {
            "type": "DRUG",
            "name": "Escitalopram + Placebo",
            "description": "Participants randomized to active or placebo condition will be prescribed medication over the course of 8 weeks, with in-person follow-up visits at weeks 0, 2, 4 and 8, with follow-up phone calls on weeks 1, 3 and 6.",
            "armGroupLabels": [
              "Escitalopram + Placebo"
            ]
          },
          "pred_item": {
            "type": "DRUG",
            "name": "Placebo + Escitalopram",
            "description": "Participants received 5 mg placebo + 10 mg escitalopram daily for 8 weeks. Dose could be increased to placebo + 20 mg escitalopram at week 4 if clinically indicated.",
            "armGroupLabels": [
              "Placebo + Escitalopram"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Rate of Adherence",
            "description": "To determine whether RT2CK17 + escitalopram results in higher rates of medication adherence relative to placebo + escitalopram as measured by percentage pill count",
            "timeFrame": "8 weeks"
          },
          "pred_item": {
            "measure": "Percent Pill Count",
            "description": "100 * [number of prescribed pills – number of pills remaining]/[number of days between dispensing date and return date]",
            "timeFrame": "Week 8"
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.secondaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "measure": "Adherence Consistency",
            "description": "To determine whether RT2CK17 + escitalopram results in greater consistency of adherence relative to placebo + escitalopram as measured by percentage of doses taken on schedule within 25% of the expected time interval, defined as +/- 6 hours from the participant's breakfast time",
            "timeFrame": "8 weeks"
          },
          "pred_item": {
            "measure": "Medication Electronic Monitoring System (MEMS) Adherence",
            "description": "Percentage of doses taken on schedule within 25% of the expected time interval, defined as ±6 hours from when the participant usually took the medication, estimated by fitting a line to their dosing times",
            "timeFrame": "Week 8"
          }
        }
      ]
    }
  ]
}